Navigation Links
Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma

MONTREAL--(BUSINESS WIRE)--May 15, 2007 - Gemin X Biotechnologies Inc. announced today that a report published in the journal Blood demonstrated that its lead compound, obatoclax (GX15-070), induced cell death in vitro in Mantle Cell Lymphoma (MCL) cell lines and primary cells from 11 MCL patients. Obatoclax (GX15-070) is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis.

The study, which appears in the May 15 print edition of Blood, is titled, "The BH3-mimetic GX15-070 synergizes with Bortezomib in Mantle Cell Lymphoma by enhancing Noxa-mediated activation of Bak." It was led by Patricia Perez-Galan et al., from the Hematopathology Unit, Department of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

According to the report, GX15-070 was active in cells bearing defective DNA damage sensor genes or cell cycle regulators. Additionally, the compound synergized with bortezomib (Velcade(R)), a proteasome inhibitor, such that MCL cells became sensitized to low doses of bortezomib. Bortezomib was shown to induce the pro-survival Bcl member, Mcl-1, which causes resistance to the drug. Inhibition of Mcl-1 by GX15-070, in contrast, overcame this resistance. This positive preclinical activity of GX15-070 led to an increased activation of the apoptotic pathway, while showing no significant cytotoxic effect in normal cells from healthy donors when used both alone and in combination with bortezomib.

"The results of this study show that a small molecule inhibitor, such as obatoclax (GX15-070) that modulates the Bcl-2 pathway, is a rational approach for the treatment of MCL," said Gordon Shore, Chief Scientific Officer of Gemin X. "Its ability to enhance the effects of bortezomib by overcomi ng resistance mediated by Mcl-1 also reveals the breadth of the compound's therapeutic potential. These findings suggest that Gemin X's obatoclax (GX15-070) in combination with bortezomib may prove to be an attractive new approach in the treatment of MCL, and further support our recent initiation of this combination in a Phase 1b trial in MCL."

Gemin X is currently conducting several clinical trials of obatoclax (GX15-070) in multiple cancer types as a combination therapy and as a single agent. In addition to the Phase 1b trial in MCL, Gemin X recently initiated a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. Obatoclax (GX15-070) is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma, myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, and follicular lymphoma both as single agent and in combination with rituximab. In multiple Phase 1 studies, obatoclax (GX15-070) was well-tolerated and resulted in clinical and biological activity.

About Mantle Cell Lymphoma (MCL)

Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related cancers that affect the lymphatic system. Mantle cell lymphoma is an aggressive B-cell lymphoma that historically has been resistant to current standard chemotherapeutic approaches, making it a difficult cancer to treat. The median survival time is three years and the ten-year survival rate is only 5-10%.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 pro-survival proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers. Gemin X is privately hel d and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

Velcade(R) is a registered trademark of Millenium Pharmaceuticals.

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
jgreenleaf@macbiocom.com
or
Gemin X Biotechnologies Inc.
Diane Viens, 514-281-8989 ext.387
investor_relations@geminx.com


'"/>




Related medicine technology :

1. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
2. Gemin X Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood
3. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
4. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly and ... actions to streamline operations to more efficiently focus ... its cost structure. Global workforce reductions, including those ... expected to impact approximately 3,500 positions. ... expects annualized savings of approximately $500 million that ...
Breaking Medicine Technology:
(Date:9/21/2017)... , ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon ... Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet Gill has ... 40 Under 40 is an annual award that was started in 2003 to ...
(Date:9/21/2017)... ... September 21, 2017 , ... Hair restoration ... member survey conducted by the International Society of Hair Restoration Surgery ... 2016 rose 60 percent, with 635,189 procedures performed in 2016. , "Like ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for ... today the election of Yie-Hsin Hung to the Board of Directors. , “The ... of Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Sagora ... acquisition of Isle at Kingwood Assisted Living and Memory Care located at 24025 ... community with 55 assisted living apartments, 43 memory care apartments and 23 extended ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Coating System for clients that rely on safety and cleanliness. This unique flooring ... , Silver has been used for centuries for its antimicrobial properties. Unlike antibiotics, ...
Breaking Medicine News(10 mins):